Sort   by:  
 Page size 
Correct classification of cancer patients into subtypes is a prerequisite for acute diagnosis and effective treatment. Currently this classification relies mainly on histological assessment, but gene expression analysis bymicroarrays has shown great promise. Here we show that high accuracy, quantita...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2016-03-10 | MSV000079572 | MassIVE
Characterization of tumors at the molecular level has improved our knowledge of cancer causation and progression. Proteomic analysis of their signaling pathways promises to enhance our understanding of cancer aberrations at the functional level, but this requires accurate and robust tools. Here, we ...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2017-03-30 | MSV000080813 | MassIVE
Data from ProteomeXhchange, PXD ID: PXD002098. Experiment: TMD8(2), file: folder summary. Published as part of Mol Cell Proteomics. 2012 May;11(5):77-89 . From the Abstract: {{i}} ... Here we show that high accuracy, quantitative proteomics can robustly segregate cancer subtypes directly at the lev...
ORGANISM(S): Homo_sapiens_viruses, Human 
Data from ProteomeXchange, PXD ID: PXD002052. Experiment: TRR37, file: folder summary. Published as part of Mol Cell Proteomics. 2015 Aug 26 . From the Abstract: {{i}} ... Here, we develop a state of the art quantitative mass spectrometric pipeline to characterize formalin-fixed paraffin-embedded (...
ORGANISM(S): Homo_sapiens_viruses, Human 
The goal of this study is to identify the transcriptome differences between the two major subtypes of diffuse large B cell lymphoma (DLBCL). DLBCL is the most common form of non-Hodgkin’s lymphoma and has two major subtypes: germinal center B-cell-like (GCB) and activated B-cell-like (ABC). When c...
ORGANISM(S): Homo sapiens 
The goal of this study is to identify the effect of the transcription factor STAT3 in the two major subtypes of diffuse large B cell lymphoma (DLBCL). STAT3 is a signal transducer that, when dysregulated, becomes a powerful oncogene found in many human cancers, including DLBCL. DLBCL is the most c...
ORGANISM(S): Homo sapiens 
A key element for the development of suitable anti-cancer drugs is the identification of cancer-specific enzymatic activities that can be therapeutically targeted. Mucosa-associated lymphoid tissue transformation protein 1 (MALT1) is a proto-oncogene that contributes to tumorigenesis in diffuse larg...
ORGANISM(S): Homo sapiens 
Knowledge of essential oncogenic mutations can inspire therapeutic strategies that are synthetically lethal, affecting cancer cells bearing an oncogenic mutation while sparing normal cells. Lenalidomide is emerging as an active agent in diffuse large B cell lymphoma (DLBCL), especially for the activ...
ORGANISM(S): Homo sapiens 
Ataxia-telangiectasia mutated (ATM) kinase plays a central role in maintaining genomic integrity. In both humans and mice, ATM deficiency is associated with an increased incidence of lymphoid cancers that are primarily T cell in origin. We demonstrate here that when T cells are removed as targets fo...
ORGANISM(S): Mus musculus 
Diffuse large B cell lymphoma (DLBCL) is the most common hematologic malignancy and is characterized by a striking degree of heterogeneity. We enrolled a total of 1001 DLBCL patients and comprehensively defined the landscape of genetic mutations, copy number alterations and expression through whole-...
Sort   by:  
 Page size